Apatinib Plus SHR1210 in Advanced Mucosal Melanoma
Status:
Recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
There is still no effective treatment for advanced mucosal melanoma at present. The efficacy
of single-agent PD-1 inhibitors is less than 20%. It is urgent to explore regimens to improve
the efficacy of PD-1 inhibitors in patients with advanced mucosal melanoma. This study is
performed to explore the safety and efficacy of apatinib plus SHR-1210 in patients with
advanced mucosa melanoma whose diseases progress after chemotherapy.